Eunice You

Eunice You

Auto-generated profile, based on publicly available information

Eunice You

Department of Ophthalmology, Hôpital du Saint-Sacrement, Quebec City, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Affective Disorders
Verified
Journal Article
Closed access
KPKelly Perlman
Kelly Perlman
DBDavid Benrimoh
David Benrimoh
SISonia Israel
Sonia Israel
CRColleen Rollins
Colleen Rollins
EBEleanor Brown
Eleanor Brown
MBMarcelo T. Berlim
Marcelo T. Berlim

1 April 2019 in Current Oncology
Verified
Journal Article
Open access
EYE.L. You
E.L. You
MHM. Henry
M. Henry
AZAnthony G. Zeitouni
Anthony G. Zeitouni
Oropharyngeal cancer (OPC) has become the leading site for human papillomavirus (HPV)–associated cancers in humans. It is an epidemic that remains relatively unfamiliar to most physicians, potentially delaying diagnosis and treatment. Traditionally, cancers involving the head and neck have occurred in smokers and in those with a significant alcohol history. Typically, HPV-positive opc presents in a younger, healthier population with a different set of risk factors and good prognosis for survival. However, many head-and-neck cancer patients, including those with HPV-positive disease, develop lifelong disabilities because of the morbid nature of their treatments, and those patients have the highest level of unmet needs in studies spanning cancer sites. Knowledge of this epidemic, a high index of suspicion, and an understanding of how the tumours present in clinical practice can help physicians to make an early diagnosis, thus sparing the patient significant morbidity from treatments associated with more advanced disease stages. Furthermore, recognizing that these patients have distinct psychosocial needs and implementing a collaborative team approach is critical to providing optimal care and improving quality of life in the survivorship period.

9 June 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
EYEunice You
Eunice You
VLVincent Lin
Vincent Lin
TMTamara Mijovic
Tamara Mijovic
AEAntoine Eskander
Antoine Eskander
MCMatthew G. Crowson
Matthew G. Crowson

1 October 2020 in World Neurosurgery
Verified
Journal Article
Closed access
RBRakan Bokhari
Rakan Bokhari
EYEunice You
Eunice You
MBMohamad Bakhaidar
Mohamad Bakhaidar
KBKhalid Bajunaid
Khalid Bajunaid
OLOliver Lasry
Oliver Lasry
Saleh Salem BaeesaSaleh Salem Baeesa
Saleh Salem Baeesa

1 March 2019 in World Neurosurgery
Verified
Journal Article
Closed access
RBRakan Bokhari
Rakan Bokhari
EYEunice You
Eunice You
FZFrederick Zeiler
Frederick Zeiler
MBMohamad Bakhaidar
Mohamad Bakhaidar
KBKhalid Bajunaid
Khalid Bajunaid
JMJudith Marcoux
Judith Marcoux

15 March 2023 in Survey of Ophthalmology
Verified
Journal Article
Open access
EYEunice Linh You
Eunice Linh You
MHMélanie Hébert
Mélanie Hébert
TJTony Shicheng Jin
Tony Shicheng Jin
SBSerge Bourgault
Serge Bourgault
MCMathieu Caissie
Mathieu Caissie
ADAli Dirani
Ali Dirani
We compare efficacy of treatments for chronic central serous chorioretinopathy (CSCR) > 3 months. Four treatment classes were considered: photodynamic therapy (PDT), subthreshold laser therapies (SLT), mineralocorticoid receptor antagonists (MRA) and antivascular endothelial growth factor (anti-VEGF) agents. Pairwise and network meta-analyses (NMA) of the primary outcomes (complete resolution of subretinal fluid (SRF), mean change in best corrected visual acuity (BCVA as logMAR) and mean change in SRF) and secondary outcomes (mean change in central retinal thickness, and central choroidal thickness (μm), recurrence of SRF, and adverse events) at 3, 6, and 12 months were compared. Confidence in Network Meta-Analysis (CINeMA) informed the certainty of NMA evidence. Eleven RCTs of 458 eyes (450 patients) were included. NMA at 3 months showed that both PDT and SLT were superior to control for resolution of SRF (OR 4.83; 95% CI 1.72-13.55 and 2.27; 1.14-4.49, respectively) and SLT was superior to control for improving BCVA (MD -0.10; -0.17 to -0.04). PDT was superior to SLT for improving CRT (MD -42.88; -75.27 to -10.50). On probability ranking, PDT and SLT were consistently the best-ranked treatments for each outcome at 3 months, but low confidence of evidence and paucity of studies preclude definitive conclusions.